AU2014233757B2 - Quinolines derivatives as novel anticancer agents - Google Patents

Quinolines derivatives as novel anticancer agents

Info

Publication number
AU2014233757B2
AU2014233757B2 AU2014233757A AU2014233757A AU2014233757B2 AU 2014233757 B2 AU2014233757 B2 AU 2014233757B2 AU 2014233757 A AU2014233757 A AU 2014233757A AU 2014233757 A AU2014233757 A AU 2014233757A AU 2014233757 B2 AU2014233757 B2 AU 2014233757B2
Authority
AU
Australia
Prior art keywords
phenyl
quinoline
piperidin
chloro
hydrochloride salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014233757A
Other languages
English (en)
Other versions
AU2014233757A1 (en
Inventor
Firas BASSISSI
Antoine Beret
Sonia BRUN
Claire CAMUS
Jerome Courcambeck
Philippe Halfon
Jean Pierre NALLET
Gregory NICOLAS
Serge Petit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genoscience Pharma SAS
Original Assignee
Genoscience Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma SAS filed Critical Genoscience Pharma SAS
Publication of AU2014233757A1 publication Critical patent/AU2014233757A1/en
Application granted granted Critical
Publication of AU2014233757B2 publication Critical patent/AU2014233757B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014233757A 2013-03-18 2014-03-13 Quinolines derivatives as novel anticancer agents Ceased AU2014233757B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361802891P 2013-03-18 2013-03-18
US61/802,891 2013-03-18
PCT/IL2014/050273 WO2014147611A1 (en) 2013-03-18 2014-03-13 Quinolines derivatives as novel anticancer agents

Publications (2)

Publication Number Publication Date
AU2014233757A1 AU2014233757A1 (en) 2015-08-27
AU2014233757B2 true AU2014233757B2 (en) 2017-12-21

Family

ID=51579387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014233757A Ceased AU2014233757B2 (en) 2013-03-18 2014-03-13 Quinolines derivatives as novel anticancer agents

Country Status (13)

Country Link
US (1) US10179770B2 (enExample)
EP (1) EP2976333B1 (enExample)
JP (1) JP2016519091A (enExample)
KR (1) KR20150132192A (enExample)
CN (1) CN105102442B (enExample)
AU (1) AU2014233757B2 (enExample)
BR (1) BR112015023948A2 (enExample)
CA (1) CA2902734A1 (enExample)
MX (1) MX2015013396A (enExample)
NZ (1) NZ710854A (enExample)
SG (1) SG11201506385WA (enExample)
WO (1) WO2014147611A1 (enExample)
ZA (1) ZA201506880B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
LT3046584T (lt) * 2013-09-16 2017-10-10 Astrazeneca Ab Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2931804A1 (en) * 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Piperidine and piperazine derivatives and their use in treating viral infections and cancer
EP3206689B1 (en) 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
EP3212629B1 (en) * 2014-10-31 2018-10-24 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new anticancer agents
MY194461A (en) 2015-11-06 2022-11-30 Neurocrine Biosciences Inc N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
WO2017136451A1 (en) * 2016-02-01 2017-08-10 Regenacy Pharmaceuticals, Llc Hdac1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disorders
WO2017191599A1 (en) * 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
CN106008339B (zh) * 2016-06-08 2018-09-07 上海准视生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3515449B1 (en) 2016-09-26 2023-07-12 Dana-Farber Cancer Institute, Inc. Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
CN106619633B (zh) * 2016-12-16 2019-05-31 江苏大学 Fpthq在制备治疗卵巢癌的药物中的应用
CN106727559B (zh) * 2016-12-16 2019-05-31 江苏大学 7-mdt在制备治疗卵巢癌的药物中的应用
CN106619634B (zh) * 2016-12-16 2019-05-31 江苏大学 化合物4-bpt在制备治疗卵巢癌药物中的应用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN110437149B (zh) * 2019-08-20 2021-01-29 大连民族大学 抗肿瘤活性的天然萘基异喹啉类化合物及其组合物、应用
AU2020332367A1 (en) * 2019-08-22 2022-02-17 Biohaven Therapeutics Ltd. Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN115108977B (zh) * 2021-03-19 2024-11-29 南京正大天晴制药有限公司 一种瑞戈非尼的制备方法
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法
CN115745889B (zh) * 2022-12-07 2025-03-14 中国人民解放军空军军医大学 一类含有2-芳基-4-取代喹啉结构的化合物及其制备方法与应用
CN118164954B (zh) * 2024-03-13 2024-09-27 江苏蒙博生物工程科技有限公司 一种基于10-羟基苯并[h]喹啉荧光母核的荧光探针、制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1886781A (en) * 1932-11-08 Multiplying mechanism for calculating machines
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
WO1998057931A2 (en) * 1997-06-19 1998-12-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1886481A (en) 1927-11-07 1932-11-08 Soc Of Chemical Ind Unilaterally acylated diamines and process of making same
JPH02129169A (ja) * 1988-11-08 1990-05-17 Ube Ind Ltd キノリン化合物およびその医薬用途
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
HRP20040716A2 (en) * 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
US20100150844A1 (en) 2006-07-28 2010-06-17 The Johns Hopkins University Use of 8-quinolinol and its analogs to target cancer stem cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1886781A (en) * 1932-11-08 Multiplying mechanism for calculating machines
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
WO1998057931A2 (en) * 1997-06-19 1998-12-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
D SPINKS ET. AL., "Investigation of Trypanthione Reductase as a Drug Target in Trypanosoma brucei.", CHEMMEDCHEM, (20091118), vol. 4, doi:10.1002/cmdc.200900262, pages 2060 - 9 *
E. PALIAKOV ET. AL., "Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG oligodeoxynucleotides.", BIOORGANIC AND MEDICINAL CHEMISTRY, (20060929), vol. 15, pp 324 - 332 *
H. GILMAN ET. AL., "Some 7-Chloroquinolines Patterned as "Open Models" of Aterbin", JOURNAL OF ORGANIC CHEMISTRY, (19470101), vol. 69, pages 123 - 4 *
J. A. CASSEL ET. AL., "Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function.", BIOCHIMIE, (20120529), vol. 94, doi:10.1016/j.biochi.2012.05.020, pages 1974 - 1981 *
J. B. CHAIRES ET. AL., "Triplex Selective 2-(2Naphthyl)quinoline Cmpounds: Origins of Afffinity and New Design Principles.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20030521), vol. 125, no. 24, doi:10.1021/ja034181r, pages 7272 - 83 *
K. E. ANDERSON ET. AL., "Oxadiazoles as bioisosteric transformations of carboxylic functionalities. II.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (19960301), vol. 31, pages 417 - 425 *
L. MANZEL ET. AL., "Antagonism of Immunostimulatory CpG Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (19990820), vol. 291, no. 3, pp 1337 - 47 *
L. STREKOWSKI ET. AL., "Structure-Activity Relationship Analysis of Substituted 4-Quinolinamindes, Antagonists of Immunostimulatory CpG Oligodeoxynucleotides.", BIOORGANIC AND MEDICINAL CEMISTRY LETTERS, (19990715), vol. 9, pages 1819 - 24 *
L. STREKOWSKI ET. AL., "Synthesis and Activity of Substituted 2-Phenylquinolin-4-amines, Antagonists of Immunostimulatory CpG-Oligodeoxynucleotides.", JOURNAL OF MEDICINAL CHEMISTRY, (20030220), vol. 46, no. 7, pp 1242 - 9 *
L. STREKOWSKI ET. AL., "Synthesis and Strucutre-DNA Binding Relationship Analysis of DNA Triple-Helix Specific Intercalators.", JOURNAL OF MEDICINAL CHEMISTRY, (19961015), vol. 39, no. 20, pages 3980 - 3 *
M. SAY ET. AL., "Synthesis of 2-Phenylquinolin-4-amines Substituted with Diverse Amino and Amnoalkyl Groups.", JOURNAL OF HETEROCYCLIC CHEMISTRY, (20061101), vol. 43, pages 1613 - 20 *
R. K. PRESTON ET. AL., "Further Investigations of Heterocyclic Alkylating Agents.", JOURNAL OF MEDICINAL CHEMISTRY, (19640701), vol. 7, pages 471 - 480 *
R. M. PECK ET. AL., "Mono- and Difunctional Analogs of Some Quinoline and Acridine Nitrogen Mustards", JOURNAL OF ORGANIC CHEMISTRY, (19600901), vol. 26, pages 3409 - 14 *
S-J. UM ET AL., "Synthesis of Novel Quinolinecarboxamide Derivatives with Estrogenic Activity", Bull. Korean Chem. Soc., 2003, Vol. 24, No. 5, pp 677-680 *
Y. MIKATA ET. AL., "Effect of side chain location in (2-aminoethyl)-aminomethyl-2-phenyl-quinolines as antitumor agents.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (19980601), vol. 8, pages 1243 - 1248 *

Also Published As

Publication number Publication date
CN105102442A (zh) 2015-11-25
CN105102442B (zh) 2018-11-09
EP2976333B1 (en) 2018-08-08
EP2976333A4 (en) 2016-08-31
JP2016519091A (ja) 2016-06-30
SG11201506385WA (en) 2015-10-29
AU2014233757A1 (en) 2015-08-27
BR112015023948A2 (pt) 2017-07-18
EP2976333A1 (en) 2016-01-27
NZ710854A (en) 2019-06-28
CA2902734A1 (en) 2014-09-25
WO2014147611A1 (en) 2014-09-25
US20160280653A1 (en) 2016-09-29
MX2015013396A (es) 2016-07-08
WO2014147611A8 (en) 2014-11-20
US10179770B2 (en) 2019-01-15
ZA201506880B (en) 2019-12-18
KR20150132192A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
AU2014233757B2 (en) Quinolines derivatives as novel anticancer agents
US20230233692A1 (en) Compounds for targeted degradation of ret
US20210198256A1 (en) Compounds for the degradation of brd9 or mth1
JP6588546B2 (ja) 新規抗癌剤としての置換２，４ジアミノキノリン
WO2017197056A1 (en) Bromodomain targeting degronimers for target protein degradation
KR20240018446A (ko) 돌연변이 braf의 분해를 위한 요법
KR20170095882A (ko) 트리아졸로피리미딘 화합물 및 그의 용도
US20240158418A1 (en) EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
WO2025137605A1 (en) Compounds for targeted degradation of proto-oncogene tyrosine protein kinase receptor
WO2024179547A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
KR20250116017A (ko) Ret-ldd 단백질 억제제
KR20250145679A (ko) Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체
NZ731345B2 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
HK1240587B (zh) 作为新抗癌药的被取代的2，4二氨基-喹啉
BR112017018637B1 (pt) Composto e seus usos, composição farmacêutica e seus usos e kit para tratamento e prevenção de doenças neoplásicas e não neoplásicas proliferativas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired